Amgen Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Expenses" stands at 15.13 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Amgen Inc's third quarter result of 3.95 Billion USD for the item "Operating Expenses" represents an increase of 12.44 percent compared to it's second quarter result.
Also, Amgen Inc's third quarter result of 3.95 Billion USD for the item "Operating Expenses" represents an increase of 25.52 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Amgen Inc's third quarter result of 15.13 Billion USD for the item "Operating Expenses" represents an increase of 5.61 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 12.40 percent compared to the value the year prior.
The 1 year change in percent is 12.40.
The 3 year change in percent is 46.68.
The 5 year change in percent is 51.38.
The 10 year change in percent is 64.03.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Expenses | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Expenses | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Expenses | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Expenses | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Expenses | 280,205,508,085.11 |